Stock A314130 GENOME & COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

All News Genome & Company

Equities

A314130

KR7314130006

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
6,710 KRW +2.29% Intraday chart for Genome & Company -4.55% -46.28%
Jan. 24 Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI CI
2023 Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI
CI
Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial
CI
Genome & Company announced that it has received KRW 23 billion in funding from a group of investors
CI
Genome & Company announced that it expects to receive KRW 23 billion in funding from a group of investors
CI
Genome & Company announced that it has received KRW 34.34975035 billion in funding from a group of investors
CI
Genome & Company announced that it expects to receive KRW 34.34975035 billion in funding from a group of investors
CI
Genome and Company Announces Clinical Trial Collaboration with Merck & Co., Inc
CI
Microbiome CDMO, List Labs, Partners with Genome And Company, to Create Global Microbiome Research, Development, and Manufacturing Powerhouse
CI
Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index
CI
Genome & Company agreed to acquire a 60% stake in List Biological Laboratories, Inc. for $27 million.
CI
Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study
CI
Genome & Company and Debiopharm Join Forces to Create New Highly Specific Therapies for Cancer Patients
CI
Genome & Company Announces First Patient Dosed in Phase 1/1B Study of GEN-001
CI
Genome & Company announced that it expects to receive KRW 19.99999001 billion in funding from Korea Development Bank, Investment Arm
CI
Scioto Biosciences, Inc. announced that it has received $26.5 million in funding from Genome & Company and other investors
CI
Scioto Biosciences, Inc. announced that it expects to receive $6.50074 million in funding
CI
Genome & Company announced that it has received KRW 4.00002 billion in funding
CI
Genome & Company announced that it expects to receive KRW 4.00002 billion in funding
CI
Genome & Company announced that it has received KRW 3.62991 billion in funding
CI
Genome & Company Receives FDA IND Clearance for GEN-001, its First Anti-Cancer Microbiome Therapeutic
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A314130 Stock
  4. News Genome & Company